IRIDEX Corporation cannot accurately predict the impact to glaucoma probes and system sales that will result from the reimbursement changes of the five LCDs as customers and prospects evaluate their usage of probes and system purchases. Given this uncertainty, guidance for 2023 has been withdrawn as the impact to Cyclo G6 system and probe sales is evaluated further.